Evidence date · 2021-06-06 · Research note 2 of 2
1 2
See current Track status →
Since the previous research note · Partly supported
Track continuity
Since the previous research note: A striking return of function in three people with advanced lung cancer
Previous expectation: Larger studies might clarify whether checkpoint treatment offers meaningful benefit with acceptable harms to patients whose daily function is very limited.
What this study adds: This 2021 synthesis pools 67 studies and finds lower response and shorter survival in the poorer-function group, while its severe adverse-event estimate shows no clear group difference. It still cannot determine treatment benefit relative to another care option.
What changed in this study
For people with advanced lung cancer who have difficulty with everyday activities, the evidence points in two different directions: tumors were less likely to respond to immune checkpoint treatment, while severe side effects did not show a clear difference from those seen in patients functioning better. That contrast matters, but it does not answer the larger question of whether treatment helps patients with limited function compared with another care option.
A 2021 systematic review and meta-analysis pooled results from 67 interventional and observational studies, covering 26,442 people with non-small cell lung cancer (NSCLC). The authors compared patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or higher with those at 0 or 1. Performance status is a clinical rating of how well a person can manage daily activities; a higher score indicates greater difficulty. The analysis focused on people treated with immune checkpoint inhibitors, medicines that help the immune system recognize and attack cancer.
Tumor responses were less common in the poorer-function group
The pooled odds ratio for objective response was 0.46, with a 95% confidence interval of 0.39 to 0.54. Objective response means that a tumor shrank enough to meet the study’s response criteria. An odds ratio below 1 means the poorer-function group had lower odds of this outcome than the group with a score of 0 or 1. Here, the estimated odds were less than half as high, though that comparison is not the same as saying that fewer than half as many people responded.
Disease control was also less likely in the poorer-function group. Its pooled odds ratio was 0.39, with a 95% confidence interval of 0.33 to 0.48. Disease control is broader than tumor shrinkage: it includes responses as well as cases in which disease did not progress during the relevant assessment. The lower estimate therefore suggests a difference across more than the subset whose tumors shrank.
These are relative comparisons between groups receiving checkpoint inhibitors. They do not tell a reader the absolute chance that a particular person’s tumor will respond, and they cannot be used to predict an individual outcome.
Survival differences varied across studies
The analysis also compared progression-free survival—the time until cancer progresses or death occurs—and overall survival, the time until death from any cause. For both measures, the pooled hazard ratio was higher in the group with performance status of 2 or higher: 2.17 for progression-free survival (95% CI 1.96–2.39) and 2.76 for overall survival (95% CI 2.43–3.14). For progression-free survival, the higher ratio reflects a higher rate of progression or death; for overall survival, it reflects a higher rate of death from any cause. They are not direct measures of how many months any one patient might gain or lose.
Results varied considerably among studies for these time-related outcomes. The I² statistic, which describes how much observed variation reflects differences among studies rather than chance alone, was 65% for progression-free survival and 76% for overall survival. Those values counsel against treating either pooled estimate as a uniform result for every setting or patient group. The analysis summarizes a broad pattern across varied studies; the size of the difference was not identical throughout the evidence.
Severe side effects showed no clear separation
For severe adverse events—those graded 3 or higher—the pooled odds ratio was 1.12, with a 95% confidence interval from 0.84 to 1.48. The estimate is close to 1, and its confidence interval includes 1, so the analysis did not show a clear difference between the performance-status groups in these events.
That finding is not proof that safety was identical. The interval is compatible with lower or higher odds in the poorer-function group, as well as little difference. It also concerns severe adverse events as measured in the studies, not every possible harm or a particular patient’s risk. The authors described the overall safety profile as comparable across groups, while the estimate itself leaves room for uncertainty.
A treated-group comparison cannot settle treatment benefit
The review compares outcomes among people who received checkpoint inhibitors, grouped by their performance status. That design can show how outcomes differed between the groups during treatment, but it does not isolate what treatment contributed for patients with a score of 2 or higher. To answer that question, researchers would need a comparison with another care option that can distinguish treatment effects from the other differences between patients and studies.
The authors called for prospective randomized studies to determine whether patients with poorer performance status benefit from checkpoint inhibitors. Until evidence makes that treatment comparison, lower response and shorter survival among treated patients should not be mistaken for proof that the medicines do—or do not—help this group compared with alternatives.
When lung cancer treatment choices could become clearer
Stronger comparative evidence could help clinicians and patients with limited daily function judge when checkpoint treatment offers enough benefit to warrant its harms. That practical choice depends on studies establishing whether treatment improves outcomes for this group compared with another care option, while also clarifying the risks they may face. The 2021 synthesis describes differences among treated patients; it leaves that benefit question open.
Key Sources
- Primary source: Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis.
DOI or Journal Page · Review or Meta-Analysis · 2021-06-06